NovaBridge’s Visara Plans To Develop HT006.2.2 As VIS-102, Second Clinical-Stage Program, Expanding Its Ophthalmology Portfolio Beyond Retinal Vascular Disease Into Ocular Surface Disease
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage
Share
Why It Matters
NovaBridge's eye-medicine team is adding a second drug project. They bought rights to work on a new eye surface disease treatment.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.